Another Court Ruling Rejects RCT Standard For Supplement Claims
This article was originally published in The Rose Sheet
Executive Summary
Two years after Bayer prevailed against FTC's demand for RCTs to substantiate claims for its Phillips Colon Health probiotic, a judge dismisses a class action complaint targeting the product, saying the plaintiffs did not support their argument and their expert expected supplements to be evaluated as drugs.
You may also be interested in...
Clinical Trials Recommended For Pamprin Botanicals PMS Claims After Challenge By Bayer
Focus Consumer Healthcare appeals NAD recommendation to pull or modify majority of express and implied claims on Pamprin Botanical product packaging, in advertising and Amazon listings challenged by Bayer Consumer.
Does FTC Health Ads Guide Read Like Rulemaking, Ignore Court Decisions On Requiring RCTs?
“I'm not sure they shouldn’t have done a notice of proposed rulemaking,” says attorney Claudia Lewis. From previous guidance, “the FTC has taken it a step in the different direction that you need robust scientific evidence, in their mind robust scientific evidence means clinical data.”
Glutamine Claim Class Action Against GNC Gets Wide Berth For Relevant Studies
An Illinois federal judge denies GNC motion to dismiss based partly on argument that studies of products with different formulations or delivery formats than the challenged Pro Performance supplements are inappropriate as evidence for the complaint alleging consumer fraud.